PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:36 AM ET

Sponsor Check › Person

SS
No photo found yet (own website and image search run after this page is viewed)

Stephen Squinto

Named as an officer, director or promoter on SEC Form D filings · CT, NH, NY, MA, PA, NJ · Oct 23, 2015 → Sep 29, 2026

16deals (issuers)
$964.3Mreported sold
312investors
30Form D filings
2015–2026years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:35 AM ET · SEC enforcement last checked: Oct 24, 2026, 12:07 AM ET

The short version

Stephen Squinto is listed as an executive officer, director, and promoter on 30 SEC Form D filings by 16 issuers between Dec 2009 and Sep 2026. Largest by amount reported sold: Compass Therapeutics, Inc. (Cambridge, MA — industry reported as "Other" — 2020; $195.3M reported sold to 114 investors), SpringWorks Therapeutics, Inc. (Stamford, CT — other health care — 2019; $125M reported sold to 26 investors), 270 Healthcare Growth Fund I LP (New York, NY — pooled investment fund — 2025–2026; $113.9M reported sold to 27 investors), 270 Healthcare Growth Fund I (LUX) SCSp-RAIF (Luxembourg, Luxembourg (as filed: N4) — pooled investment fund — 2025–2026; $113.9M reported sold to 18 investors), Compass Therapeutics LLC (Cambridge, MA — biotechnology — 2015–2016; $110.2M reported sold to 20 investors) and 11 more (all listed below).

What this means That is a lot of deals — 16 separate companies raised money with this person listed as executive officer, director, and promoter, over about 17 years. Across those companies the filings report $964.3M sold in total.

Listed alongside Gaurav Gupta (9 shared filings), Patrick McGoldrick (9 shared filings), Samantha Beattie (9 shared filings), Anya Schiess (7 shared filings), Carl L. Gordon (7 shared filings) and 68 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Stephen. Each name links to their own page.

The issuers belong to 4 sponsor groups: J P Morgan (681 issuers, $310.46B reported sold, 2008–2026), Springworks Therapeutics (2 issuers, $137.8M reported sold, 2017–2019), Compass Therapeutics (2 issuers, $170.7M reported sold, 2014–2020) and Arvinas (2 issuers, $36M reported sold, 2013–2019).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 30 public filings for Stephen Squinto and found 11 differences, 2 worth asking the sponsor about: 4 paid sellers are listed without a CRD number; Stephen Squinto is no longer listed on the Jul 16, 2018 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Stephen Squinto has not run yet — it is #15,119 of 19,028 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 31 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:35 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (checked Oct 24, 2026) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 12:07 AM ET.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:35 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

11 differences found between the filings for Stephen Squinto — 2 worth asking about (compared 30 filings on Oct 24, 2026)

Worth asking · Sep 5, 2023 – Nov 13, 2023

4 paid sellers are listed without a CRD number

Paid seller listed without a CRD number: JPMORGAN ASSET MANAGEMENT (JAPAN) LIMITED — 270 Life Sciences Private Capital Employee Fund I LP · Paid seller listed without a CRD number: JPMORGAN ASSET MANAGEMENT (UK) LIMITED — 270 Life Sciences Private Capital Employee Fund I LP · Paid seller listed without a CRD number: JPMorgan Asset Management (Japan) Limited — 270 Life Sciences Private Capital Fund I LP · Paid seller listed without a CRD number: JPMorgan Asset Management (Japan) Limited — 270 Life Sciences Private Capital Fund I (Lux) SCSp-RAIF

What this means Without a CRD number we cannot look a seller up on BrokerCheck. Ask who they are and whether they are registered.

Form D · Nov 13, 2023 ↗BrokerCheck search: JPMORGAN ASSET MANAGEMENT (JAPAN) LIMITED ↗270 Life Sciences Private Capital Employee Fund I LP — PartnerFacts page ↗BrokerCheck search: JPMORGAN ASSET MANAGEMENT (UK) LIMITED ↗
Sources
Worth asking · Sep 21, 2016 – Jul 16, 2018

Stephen Squinto is no longer listed on the Jul 16, 2018 amendment — Compass Therapeutics LLC

Stephen Squinto appears on the Sep 21, 2016 Form D/A (director) but not on the Jul 16, 2018 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Sep 21, 2016 ↗Form D/A · Jul 16, 2018 ↗Stephen Squinto — PartnerFacts page ↗Compass Therapeutics LLC — PartnerFacts page ↗
Sources
Note · Aug 21, 2019 – Sep 6, 2019

Form D filed 16 days after the first sale — Passage BIO, Inc.

The filing says the first sale was Aug 21, 2019. The Form D was filed Sep 6, 2019 — 16 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 1 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Sep 6, 2019 ↗Passage BIO, Inc. — PartnerFacts page ↗
Sources
Note · Dec 9, 2010 – Dec 28, 2021

4 offerings changed their target amount between filings

Offering amount changed between filings — Gennao Bio, Inc. · Offering amount changed between filings — UCAN Co · Offering amount changed between filings — UCAN Co · Offering amount changed between filings — Compass Therapeutics LLC

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · May 21, 2021 ↗Form D/A (later) · Dec 28, 2021 ↗Gennao Bio, Inc. — PartnerFacts page ↗Form D (earlier) · Apr 19, 2012 ↗
Sources
Note · Aug 18, 2017 – Dec 8, 2022

5 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Gennao Bio, Inc. (latest filing Dec 8, 2022) · No amendment in the last 12 months on an offering that may still be open — Gennao Bio, Inc. (latest filing Dec 28, 2021) · No amendment in the last 12 months on an offering that may still be open — Compass Therapeutics, Inc. (latest filing Jul 1, 2020) · No amendment in the last 12 months on an offering that may still be open — Passage BIO, Inc. (latest filing Sep 6, 2019) · No amendment in the last 12 months on an offering that may still be open — SpringWorks Therapeutics, LLC (latest filing Sep 1, 2017)

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Dec 8, 2022 ↗Gennao Bio, Inc. — PartnerFacts page ↗Form D/A · Dec 28, 2021 ↗Form D · Jul 1, 2020 ↗
Sources
Note · Dec 24, 2009 – Jul 1, 2020

Stephen Squinto is written 3 different ways on the filings

listed as "Stephen Squinto" on 24 filings (from Dec 24, 2009), and "Stephen Squinto, Sr." on 4 filings (from Dec 9, 2010), and "Stephen P. Squinto" on 2 filings (from Jul 1, 2020).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Dec 24, 2009 ↗Form D/A · Dec 9, 2010 ↗Form D · Jul 1, 2020 ↗Stephen Squinto — PartnerFacts page ↗
Sources
Note · Aug 9, 2024 – Sep 11, 2025

Same name, different state: "Stephen Squinto" (CA) is a separate record

This page covers filings where the address state is CT or NH or NY or MA or PA or NJ. A separate record, "Stephen Squinto" with address state CA, is listed on 2 filings — most recently by Enlaza Therapeutics, Inc. (Sep 11, 2025). Both records have filings in the same period (Aug 9, 2024 to Sep 11, 2025).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Stephen Squinto (CA) — PartnerFacts page ↗Form D · Sep 11, 2025 ↗Enlaza Therapeutics, Inc. — PartnerFacts page ↗Stephen Squinto (CT,NH,NY,MA,PA,NJ) — this page ↗
Sources
Note · Sep 15, 2021

Same name, different state: "Stephen Squinto" (IL) is a separate record

This page covers filings where the address state is CT or NH or NY or MA or PA or NJ. A separate record, "Stephen Squinto" with address state IL, is listed on 1 filing — most recently by VANQUA BIO, INC. (Sep 15, 2021). Both records have filings in the same period (Sep 15, 2021).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Stephen Squinto (IL) — PartnerFacts page ↗Form D · Sep 15, 2021 ↗VANQUA BIO, INC. — PartnerFacts page ↗Stephen Squinto (CT,NH,NY,MA,PA,NJ) — this page ↗
Sources
Note · Mar 30, 2021

Same name, different state: "Stephen P Squinto" (NY) is a separate record

This page covers filings where the address state is CT or NH or NY or MA or PA or NJ. A separate record, "Stephen P Squinto" with address state NY, is listed on 1 filing — most recently by Chemomab Therapeutics Ltd. (Mar 30, 2021). Both records have filings in the same period (Mar 30, 2021).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Stephen P Squinto (NY) — PartnerFacts page ↗Form D · Mar 30, 2021 ↗Chemomab Therapeutics Ltd. — PartnerFacts page ↗Stephen Squinto (CT,NH,NY,MA,PA,NJ) — this page ↗
Sources
Note · Jul 1, 2015 – Apr 21, 2025

4 address changes between filings

Address moved from New York, NY to Watertown, MA — Averna Therapeutics Inc. · Address moved from New York, NY to Pennington, NJ — Gennao Bio, Inc. · Address moved from New Haven, CT to New York, NY — ARVINAS, INC. · Address moved from Hanover, NH to Cambridge, MA — Compass Therapeutics LLC

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Apr 17, 2024 ↗Form D/A · Apr 21, 2025 ↗Averna Therapeutics Inc. — PartnerFacts page ↗Form D · May 21, 2021 ↗
Sources
Note · Dec 24, 2009 – Sep 29, 2026

Stephen Squinto is listed with 6 different address states: CT, NH, NY, MA, PA, NJ

CT on 7 filings (Dec 24, 2009 to Apr 12, 2019); NH on 1 filing (Jul 1, 2015); NY on 14 filings (Oct 23, 2015 to Sep 29, 2026); MA on 5 filings (Sep 21, 2016 to Mar 20, 2026); PA on 1 filing (Sep 6, 2019); NJ on 2 filings (Dec 28, 2021 to Dec 8, 2022).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Dec 24, 2009 ↗Form D · Jul 1, 2015 ↗Form D · Oct 23, 2015 ↗Form D/A · Sep 21, 2016 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

1 of 21 offerings reports sales commissions totalling $4,700,000; 0 report finder's fees; 1 reports proceeds to related persons totalling $1,710,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Sep 29, 2026 D/A
270 Healthcare Growth Fund I LP
File 021-559127
$0 (est.)$0 (est.)$0 (est.)
The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗		EDGAR ↗
Sep 29, 2026 D/A
270 Healthcare Growth Fund I (LUX) SCSp-RAIF
File 021-559129
$0 (est.)$0 (est.)$0 (est.)
The special shareholder is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗		EDGAR ↗
Sep 16, 2026 D
270 Life Sciences Private Capital Fund II (US) LP
File 021-597633
$0 (est.)$0 (est.)$0 (est.)
The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗		EDGAR ↗
Sep 16, 2026 D
270 Life Sciences Private Capital Fund II (Cayman) LP
File 021-597634
$0 (est.)$0 (est.)$0 (est.)
The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗		EDGAR ↗
Mar 20, 2026 D/A
Averna Therapeutics Inc.
File 021-510828
$0$0$0None listed on this filingEDGAR ↗
Nov 13, 2023 D
270 Life Sciences Private Capital Employee Fund I LP
File 021-496947
$0 (est.)$0 (est.)$0 (est.)
The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. MORGAN INSTITUTIONAL INVESTMENTS INC. BrokerCheck CRD 102920 ↗
JPMORGAN ASSET MANAGEMENT (JAPAN) LIMITED no CRD number reported
JPMORGAN ASSET MANAGEMENT (EUROPE) S.A.R.L. BrokerCheck CRD 304190 ↗
JPMORGAN ASSET MANAGEMENT (UK) LIMITED no CRD number reported		EDGAR ↗
Sep 5, 2023 D
270 Life Sciences Private Capital Fund I LP
File 021-491365
$0 (est.)$0 (est.)$0 (est.)
The special limited partner is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗
JPMorgan Asset Management (UK) Limited BrokerCheck CRD 135960 ↗
JPMorgan Asset Management (Japan) Limited no CRD number reported
JPMorgan Asset Management (Europe) S.a r.l. BrokerCheck CRD 304190 ↗		EDGAR ↗
Sep 5, 2023 D
270 Life Sciences Private Capital Fund I (Lux) SCSp-RAIF
File 021-491366
$0 (est.)$0 (est.)$0 (est.)
The special shareholder is entitled to carried interest. The investment manager is entitled to a management fee. The carried interest and management fee are fully discussed in the Issuer's confidential offering materials.
J.P. Morgan Institutional Investments Inc. BrokerCheck CRD 102920 ↗
JPMorgan Asset Management (UK) Limited BrokerCheck CRD 135960 ↗
JPMorgan Asset Management (Japan) Limited no CRD number reported
JPMorgan Asset Management (Europe) S.a r.l. BrokerCheck CRD 304190 ↗		EDGAR ↗
Dec 8, 2022 D
Gennao Bio, Inc.
File 021-466966
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2021 D/A
Gennao Bio, Inc.
File 021-400266
$0$0$0None listed on this filingEDGAR ↗
Jul 1, 2020 D
Compass Therapeutics, Inc.
File 021-370112
$0$0$0None listed on this filingEDGAR ↗
Jul 1, 2020 D
Compass Therapeutics, Inc.
File 021-370115
$4,700,000$0$0Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗
B. Riley FBR, Inc. BrokerCheck CRD 25027 ↗
Katalyst Securities LLC BrokerCheck CRD 112494 ↗		EDGAR ↗
Sep 6, 2019 D
Passage BIO, Inc.
File 021-348117
$0$0$0None listed on this filingEDGAR ↗
Apr 12, 2019 D
SpringWorks Therapeutics, Inc.
File 021-337163
$0$0$0None listed on this filingEDGAR ↗
May 10, 2018 D
UCAN Co
File 021-312119
$0$0$0 (est.)None listed on this filingEDGAR ↗
Apr 5, 2018 D
ARVINAS, INC.
File 021-309449
$0$0$0
No payments other than ordinary course employment compensation is being paid to officers or managers.
None listed on this filingEDGAR ↗
Mar 9, 2018 D/A
UCAN Co
File 021-114791
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2018 D/A
UCAN Co
File 021-176983
$0$0$0None listed on this filingEDGAR ↗
Sep 1, 2017 D
SpringWorks Therapeutics, LLC
File 021-293982
$0$0$0None listed on this filingEDGAR ↗
Sep 21, 2016 D/A
Compass Therapeutics LLC
File 021-242888
$0$0$1,710,000 (est.)None listed on this filingEDGAR ↗
Oct 23, 2015 D
ARVINAS, INC.
File 021-249974
$0$0$0
No payments other than ordinary course employment compensation is being paid to officers or directors.
None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 16

Every issuer that named Stephen Squinto on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

2H
Pooled Investment Fund · group: J P Morgan

270 Healthcare Growth Fund I LP

New York, NY · Sep 29, 2025 → Sep 29, 2026 · 2 filings
  • Sep 29, 2026 · D/A · $113,926,000 sold of Indefinite · 27 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Sep 29, 2025 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $113.9M from 27 investors as of the latest filing. Stephen is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2H
Pooled Investment Fund · group: J P Morgan

270 Healthcare Growth Fund I (LUX) SCSp-RAIF

Luxembourg, Luxembourg (as filed: N4) · Sep 29, 2025 → Sep 29, 2026 · 2 filings
  • Sep 29, 2026 · D/A · $113,926,000 sold of Indefinite · 18 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Sep 29, 2025 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $113.9M from 18 investors as of the latest filing. Stephen is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2L
Pooled Investment Fund · group: J P Morgan

270 Life Sciences Private Capital Fund II (Cayman) LP

New York, NY · Sep 16, 2026
  • Sep 16, 2026 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Stephen is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2L
Pooled Investment Fund · group: J P Morgan

270 Life Sciences Private Capital Fund II (US) LP

New York, NY · Sep 16, 2026
  • Sep 16, 2026 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Stephen is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Other Health Care

Averna Therapeutics Inc.

Watertown, MA · Apr 17, 2024 → Mar 20, 2026 · 3 filings
  • Mar 20, 2026 · D/A · $84,999,995 sold of $85,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 21, 2025 · D/A · $43,769,227 sold of $85,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 17, 2024 · D · $38,769,227 sold of $85,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $85M from 13 investors (100% of the $85M target) as of the latest filing. Stephen is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2L
Pooled Investment Fund · group: J P Morgan

270 Life Sciences Private Capital Employee Fund I LP

New York, NY · Nov 13, 2023
  • Nov 13, 2023 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Stephen is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2L
Pooled Investment Fund · group: J P Morgan

270 Life Sciences Private Capital Fund I (Lux) SCSp-RAIF

Luxembourg, Luxembourg (as filed: N4) · Sep 5, 2023
  • Sep 5, 2023 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Stephen is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

2L
Pooled Investment Fund · group: J P Morgan

270 Life Sciences Private Capital Fund I LP

New York, NY · Sep 5, 2023
  • Sep 5, 2023 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

No sales reported yet as of the latest filing. Stephen is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GB
Biotechnology · group: J P Morgan

Gennao Bio, Inc.

Pennington, NJ · May 21, 2021 → Dec 8, 2022 · 3 filings
  • Dec 8, 2022 · D · $14,999,997 sold of $40,000,000 · 3 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Dr. Squinto is the Executive Chairman of the Issuer.) EDGAR ↗
  • Dec 28, 2021 · D/A · $32,500,008 sold of $55,000,012 · 7 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Dr. Squinto is the Chief Executive Officer, Executive Chairman, President and Treasurer.) EDGAR ↗
  • May 21, 2021 · D · $10,000,005 sold of $40,000,019 · 3 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Dr. Squinto is the Executive Executive Officer, Chairman, President, Treasurer and Secretary of the Issuer.) EDGAR ↗

Raised $32.5M from 7 investors (81% of the $40M target) as of the latest filing. Stephen is listed as executive officer, director, promoter on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Other · group: Compass Therapeutics

Compass Therapeutics, Inc.

Cambridge, MA · Jul 1, 2020 → Jul 1, 2020 · 2 filings
  • Jul 1, 2020 · D · $60,482,210 sold of $70,000,000 · 110 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 1, 2020 · D · $195,276,780 sold of $195,276,780 · 114 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $195.3M from 114 investors (100% of the $70M target) as of the latest filing. Stephen is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PB
Other Health Care

Passage BIO, Inc.

Philadelphia, PA · Sep 6, 2019
  • Sep 6, 2019 · D · $109,999,974 sold of $110,000,000 · 15 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $110M from 15 investors (100% of the $110M target) as of the latest filing. Stephen is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Other Health Care · group: Springworks Therapeutics

SpringWorks Therapeutics, Inc.

Stamford, CT · Apr 12, 2019
  • Apr 12, 2019 · D · $125,003,152 sold of $125,003,152 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $125M from 26 investors (100% of the $125M target) as of the latest filing. Stephen is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

UC
Biotechnology

UCAN Co

Woodbridge, CT · Dec 24, 2009 → May 10, 2018 · 6 filings
  • May 10, 2018 · D · $5,749,976 sold of $5,749,976 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 9, 2018 · D/A · $2,515,103 sold of $2,515,103 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 9, 2018 · D/A · $2,519,976 sold of $2,519,976 · 46 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 19, 2012 · D · $620,628 sold of $2,500,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 9, 2010 · D/A · $1,859,316 sold of $2,499,999 · 46 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2009 · D · $624,446 sold of $2,499,999 · 22 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10.7M from 46 investors (100% of the $5.75M target) as of the latest filing. Stephen is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Biotechnology · group: Arvinas

ARVINAS, INC.

New Haven, CT · Oct 23, 2015 → Apr 5, 2018 · 2 filings
  • Apr 5, 2018 · D · $55,000,000 sold of $55,000,000 · 22 investors · min. No minimum reported · role: Director (Manager) EDGAR ↗
  • Oct 23, 2015 · D · $41,609,999 sold of $41,609,999 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $55M from 22 investors (100% of the $55M target) as of the latest filing. Stephen is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Other Health Care · group: Springworks Therapeutics

SpringWorks Therapeutics, LLC

Baltimore, MD · Sep 1, 2017
  • Sep 1, 2017 · D · $12,815,535 sold of $103,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12.8M from 4 investors (12% of the $103M target) as of the latest filing. Stephen is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Biotechnology · group: Compass Therapeutics

Compass Therapeutics LLC

Cambridge, MA · Jul 1, 2015 → Sep 21, 2016 · 2 filings
  • Sep 21, 2016 · D/A · $45,977,738 sold of $170,205,999 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 1, 2015 · D · $15,977,535 sold of $120,977,535 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $110.2M from 20 investors (65% of the $170.2M target) as of the latest filing. Stephen is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other pages with the same name (3)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Stephen Squinto — IL, 1 issuer, Sep 15, 2021 → Sep 15, 2021 · no shared issuer
  • Stephen Squinto — CA, 1 issuer, Aug 9, 2024 → Sep 11, 2025 · no shared issuer
  • Stephen P Squinto — NY, 1 issuer, Mar 30, 2021 → Mar 30, 2021 · no shared issuer

People around Stephen 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

SB
No photo found yet (own website and image search run after this page is viewed)
Person

Samantha Beattie

Executive Officer · 9 shared filings (7 issuers) · also on 12 other issuers

Samantha Beattie is on 19 issuers in total — a repeat sponsor. Their page lists every one.

GG
No photo found yet (own website and image search run after this page is viewed)
Person

Gaurav Gupta

Executive Officer · 9 shared filings (7 issuers) · also on 1 other issuer

Gaurav Gupta is on 8 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Patrick McGoldrick

Executive Officer · 9 shared filings (7 issuers) · also on 4 other issuers

Patrick McGoldrick is on 11 issuers in total — a repeat sponsor. Their page lists every one.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carl L. Gordon

Director · 7 shared filings (5 issuers) · also on 57 other issuers

Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Anya Schiess

Executive Officer · 7 shared filings (5 issuers)

Anya Schiess is on 5 issuers in total — a repeat sponsor. Their page lists every one.

DF
No photo found yet (own website and image search run after this page is viewed)
Person

David Feldman

Director, Promoter, Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

SM
No photo found yet (own website and image search run after this page is viewed)
Person

Shoba Murali

Executive Officer, Director, Promoter · 6 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

PK
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Kaufman

Director, Executive Officer, Promoter · 6 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

KS
No photo found yet (own website and image search run after this page is viewed)
Person

Kannankote (Sri) Srikanth

Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

RR
No photo found yet (own website and image search run after this page is viewed)
Person

Ramesh Ratan

Executive Officer · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

PF
No photo found yet (own website and image search run after this page is viewed)
Person

Philip Ferneau

Director · 4 shared filings (2 issuers) · also on 11 other issuers

Philip Ferneau is on 13 issuers in total — a repeat sponsor. Their page lists every one.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas J. Schuetz

Executive Officer, Director, Promoter · 4 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph Siletto

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

ES
No photo found yet (own website and image search run after this page is viewed)
Person

Evan Sotiriou

Executive Officer · 3 shared filings (3 issuers) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

HC
No photo found yet (own website and image search run after this page is viewed)
Person

Henry Chen

Director · 3 shared filings (1 issuer) · also on 8 other issuers

Henry Chen is on 9 issuers in total — a repeat sponsor. Their page lists every one.

CD
No photo found yet (own website and image search run after this page is viewed)
Person

Chris Duke

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Roy Amariglio

Director, Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

Dylan Morris

Director · 3 shared filings (1 issuer) · also on 9 other issuers

Dylan Morris is on 10 issuers in total — a repeat sponsor. Their page lists every one.

AL
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew Levin

Director · 2 shared filings (1 issuer) · also on 20 other issuers

Andrew Levin is on 21 issuers in total — a repeat sponsor. Their page lists every one.

SC
No photo found yet (own website and image search run after this page is viewed)
Person

Sean Cassidy

Executive Officer · 2 shared filings (1 issuer) · also on 5 other issuers

Sean Cassidy is on 6 issuers in total — a repeat sponsor. Their page lists every one.

CK
No photo found yet (own website and image search run after this page is viewed)
Person

Chau Khuong

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

LR
No photo found yet (own website and image search run after this page is viewed)
Person

Liam Ratcliffe

Director · 2 shared filings (1 issuer) · also on 10 other issuers

Liam Ratcliffe is on 11 issuers in total — a repeat sponsor. Their page lists every one.

EA
No photo found yet (own website and image search run after this page is viewed)
Person

Errik Anderson

Executive Officer, Director, Promoter · 2 shared filings (1 issuer) · also on 16 other issuers

Errik Anderson is on 17 issuers in total — a repeat sponsor. Their page lists every one.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Soderstrom

Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

BA
No photo found yet (own website and image search run after this page is viewed)
Person

Ben Auspitz

Director · 2 shared filings (1 issuer) · also on 5 other issuers

Ben Auspitz is on 6 issuers in total — a repeat sponsor. Their page lists every one.

PK
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Keen

Director · 2 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Tim Shannon

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Tim Shannon is on 5 issuers in total — a repeat sponsor. Their page lists every one.

KP
No photo found yet (own website and image search run after this page is viewed)
Person

Kush Parmar

Director · 2 shared filings (1 issuer) · also on 16 other issuers

Kush Parmar is on 17 issuers in total — a repeat sponsor. Their page lists every one.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Julie Sunderland

Director · 2 shared filings (1 issuer) · also on 4 other issuers

Julie Sunderland is on 5 issuers in total — a repeat sponsor. Their page lists every one.

DP
No photo found yet (own website and image search run after this page is viewed)
Person

DEVAL PATRICK

Director · 2 shared filings (2 issuers) · also on 3 other issuers

DEVAL PATRICK is on 5 issuers in total — a repeat sponsor. Their page lists every one.

VL
No photo found yet (own website and image search run after this page is viewed)
Person

VERED BISKER-LEIB

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

DL
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel S. Lynch

Executive Officer, Director · 2 shared filings (2 issuers)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

SI
No photo found yet (own website and image search run after this page is viewed)
Person

Saqib Islam

Executive Officer, Director · 2 shared filings (2 issuers)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

GS
No photo found yet (own website and image search run after this page is viewed)
Person

Gary Sender

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

DL
No photo found yet (own website and image search run after this page is viewed)
Person

Dale Ludwig

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

Julie Hambleton

Director · 2 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

AG
No photo found yet (own website and image search run after this page is viewed)
Person

Anuj Goswami

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Stephen Squinto. Their page shows their other deals.

The team behind the deals

JP
Sponsor group

J P Morgan

681 issuers · 1990 filings · $310.46B reported sold · 2008–2026

One team, 681 deal companies. Stephen Squinto is listed on 8 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Stephen Squinto.

ST
Sponsor group

Springworks Therapeutics

2 issuers · 2 filings · $137.8M reported sold · 2017–2019

One team, 2 deal companies. Stephen Squinto is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Stephen Squinto.

CT
Sponsor group

Compass Therapeutics

2 issuers · 8 filings · $170.7M reported sold · 2014–2020

One team, 2 deal companies. Stephen Squinto is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Stephen Squinto.

A
Sponsor group

Arvinas

2 issuers · 4 filings · $36M reported sold · 2013–2019

One team, 2 deal companies. Stephen Squinto is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Stephen Squinto.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 16 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Stephen Squinto by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 16 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Stephen Squinto is listed on: none on file. No website or social profile named in Compass Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #214,149 of 374,652 in line (42 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Connecticut Judicial Branch case look-up ↗New Hampshire state courts — find the court ↗New York WebCivil Supreme ↗Massachusetts MassCourts ↗Pennsylvania UJS portal case search ↗New Jersey state courts — find the court ↗Maryland Judiciary case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Connecticut Secretary of State business search ↗New Hampshire Secretary of State business search ↗New York Secretary of State business search ↗Massachusetts Secretary of State business search ↗Pennsylvania Secretary of State business search ↗New Jersey Secretary of State business search ↗Maryland Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Stephen Squinto appears on a new Form D, or when a court case or SEC action is matched to them. See plans →